Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20183917 | 0.79 | LMNA (0.56) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL20183923 | 0.79 | LMNA (0.56) | LMNAHTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL7575151 | 0.77 | CASP3 (0.40) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5356150 | 0.75 | CHRM2 (0.37) | — | |
| SCHEMBL6200902 | 0.75 | LMNA (0.41) | LMNARAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL20183877 | 0.75 | L3MBTL1 (0.46) | LMNASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL3452817 | 0.75 | CA12 (0.51) | HTTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL7571307 | 0.74 | APP (0.44) | — | |
| SCHEMBL20183926 | 0.73 | CA12 (0.45) | ALDH1A1 | |
| SCHEMBL7974837 | 0.73 | LMNA (0.66) | LMNAHTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766857-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-09-08 | — | — | US | disclosed |
| EP-3327000-B1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | UNIV DONGGUK IND ACAD COOP (KR) | 2020-09-02 | — | — | EP | disclosed |
| US-20190071395-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-03-07 | — | — | US | disclosed |
| US-10179764-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2019-01-15 | — | — | US | disclosed |
| US-20180201573-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-07-19 | — | — | US | disclosed |
| EP-3327000-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2018-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201573-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | LMNA 1062/4885HTT 4114/4885SMN1; SMN2 3907/4885 |
| US-10766857-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | LTB4R2, CYSLTR2, LTB4R | LMNA 915/4885HTT 4002/4885SMN1; SMN2 3790/4885 |
| US-10179764-B2 | Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient | LTB4R2, CYSLTR2, LTB4R | LMNA 915/4885HTT 4002/4885SMN1; SMN2 3790/4885 |
| US-20190071395-A1 | NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | LTB4R2, CYSLTR2, LTB4R | LMNA 1062/4885HTT 4114/4885SMN1; SMN2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.